Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab

Br J Anaesth. 2018 Aug;121(2):505-508. doi: 10.1016/j.bja.2018.04.025. Epub 2018 Jun 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Anticoagulants / adverse effects*
  • Anticoagulants / pharmacokinetics
  • Blood Coagulation Tests
  • Dabigatran / adverse effects*
  • Dabigatran / antagonists & inhibitors*
  • Dabigatran / pharmacokinetics
  • Emergency Medical Services
  • Female
  • Gastrointestinal Hemorrhage / chemically induced*
  • Gastrointestinal Hemorrhage / prevention & control*
  • Humans
  • Kidney Diseases / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • idarucizumab
  • Dabigatran